BACKGROUND: In Korea, breast cancer is the most common cancer in female and its incidence is increasing recently. Moreover, breast cancer is the most common cutaneous metastasis in female. However, dermatologic disorders manifested in patients with breast cancer have not been investigated yet. OBJECTIVES: Our purpose was to study the clinical characteristics of dermatologic disorders in patients with breast cancer. METHODS: A clinical observation and review of medical records were made by analyzing 359 cases of breast cancer who visited Our Lady of Mercy hospital from 1994 to 2003. Among them, 91 cases of the patients with breast cancer showed dermatologic disorders. Their photographs of cutaneous findings and histologic specimens were reviewed by more than 2 dermatologists. RESULTS & CONCLUSIONS: 1. The mean age at the diagnosis of breast cancer was 48.74+/-11.28 years old. 2. The stages of patients with breast cancer were as follows: stage 0 (4 cases), stage 1 (48 cases), stage 2 (196 cases), stage 3 (94 cases), stage 4 (2 cases), and others (15 cases). 3. The treatments of patients with breast cancer were as follows: surgery (358 cases), radiation therapy (115 cases), chemotherapy (256 cases), combination of chemotherapy and radiation therapy (82 cases), and others (9 cases). 4. The numbers of patients developing cutaneous infections among the patients with breast cancer were as follows: bacterial infection (18 cases), fungal infection (18 cases), and viral infection (14 cases). 5. The numbers of patients developing pruritus and eczema among the patients with breast cancer were as follows: contact dermatitis (7 cases), seborrheic dermatitis (3 cases), neurodermatitis (2 cases), and others (9 cases). 6. The numbers of patients developing treatment-associated dermatologic disorders among the patients with breast cancer were as follows: urticaria (11 cases), radiodermatitis (8 cases), drug eruption (6 cases), and lymphedema (1 case). 7. The number of patients developing skin metastasis among the patients with breast cancer was 10 cases. 8. The numbers of patients developing other dermatologic disorders among the patients with breast cancer were as follows: psoriasis (4 cases), erythema multiforme (2 cases), and others (16 cases). 9. The numbers of patients developing postoperative dermatologic complications were as follows: seroma (28 cases), arm swelling and lymphedema (9 cases), wound infection (6 cases), and others (5 cases).
Arm ; Bacterial Infections ; Breast Neoplasms* ; Breast* ; Dermatitis, Contact ; Dermatitis, Seborrheic ; Diagnosis ; Drug Eruptions ; Drug Therapy ; Eczema ; Erythema Multiforme ; Female ; Humans ; Incidence ; Korea ; Lymphedema ; Medical Records ; Neoplasm Metastasis ; Neurodermatitis ; Pruritus ; Psoriasis ; Radiodermatitis ; Seroma ; Skin ; Urticaria ; Wound Infection

Pimecrolimus cream 1% has shown to be effective in patients with a variety of inflammatory cutaneous disorders. And it might be a useful modality in the treatment of seborrheic dermatitis. This prospective study was aimed at assessing the efficacy and tolerability of pimecrolimus cream 1% in the treatment of facial seborrheic dermatitis. Twenty patients were instructed to apply pimecrolimus cream 1% for 4 consecutive weeks. Assessment of the disease severity was performed at baseline and at week 1, 2, and 4. Clinical assessments of erythema, scaling, and pruritus were measured using a 4-point scale (0-3). Global assessments of the disease severity by patients and investigators were performed at each visit. Mean clinical scores of erythema, scaling, and pruritus significantly improved by 87.4%, 91.9%, and 91.5% respectively at week 4 (p<0.001). Improvements in the global assessment of disease severity determined by patients and investigators also showed excellent results. No specific adverse events other than transient burning and tingling sensations were noted. The relapse of facial seborrheic dermatitis was mostly observed between 3 to 8 weeks after the discontinuation of pimecrolimus. We suggest that the topical application of pimecrolimus cream 1% can be an effective and safe alternative for treatment of facial seborrheic dermatitis.
Adult ; Aged ; Dermatitis, Seborrheic/*drug therapy ; Erythema/drug therapy ; Face ; Female ; Follow-Up Studies ; Humans ; Korea ; Male ; Middle Aged ; Severity of Illness Index ; Tacrolimus/*analogs & derivatives/therapeutic use ; Time Factors ; Treatment Outcome